# The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

> **NCT06633042** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Bioray Laboratories** · enrollment: 18 (estimated)

## Conditions studied

- Autoimmune Disease

## Interventions

- **DRUG:** Universal BCMA-CD19 CART

## Key facts

- **NCT ID:** NCT06633042
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2025-10-12
- **Final completion:** 2025-12-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06633042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06633042, "The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06633042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*